3 results
Not approvedWill not start
reduction of fluid administration of 30%
Approved WMOCompleted
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
Approved WMOWill not start
Primary ObjectiveTo determine if an approach consisting of AV junction ablation and biventricular pacing is superior to optimal pharmacological rate control therapy in reducing total mortality at 48 months.Secondary ObjectiveTo determine if an…